Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments for Eradication

• Päätekijät: Seokin Kang (Tekijä), Nam-Hoon Kim (Tekijä), Seokhyeon Jeong (Tekijä), Jong Wook Kim (Tekijä), Jung Rock Moon (Tekijä), Yoon Suk Lee (Tekijä), Jun Hyuk Son (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Yong Chan Lee, 2024-06-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Objectives Tegoprazan, a novel potassium-competitive acid blocker with rapid and effective antisecretory activity, was approved for the treatment of Helicobacter pylori infections in Korea in March 2020. However, real-world data regarding tegoprazan-based therapies are scarce. We compared the effica...